Leadership Changes at Bristol-Myers Squibb: Who's the Next to Be Let Go?

On April 26, 2023, Bristol-Myers Squibb (BMS) announced a significant development that placed the company in the spotlight. The announcement revealed a major leadership change: after eight years as CEO, Dr. Giovanni Caforio would step down, passing leadership to Chief Commercialization Officer Chris Boerner.

This leadership transition not only marked the end of a chapter in Caforio’s career but also posed unprecedented challenges for Boerner. Bristol-Myers Squibb is facing the severe challenge of a patent cliff, which is a critical test for the company. To ensure a smooth transition, Caforio’s resignation did not take immediate effect; instead, a carefully planned transition period lasted until November 1, 2023, when he formally handed over leadership, ushering in a new era for Bristol-Myers Squibb.

This leadership change has profound implications for BMS and its closely associated biotechnology partners. Recently, the company announced the termination of cell therapy collaboration agreements with Century Therapeutics and Immatics, marking significant decisions under Boerner’s tenure—and they are unlikely to be the last.

Under Caforio's leadership, BMS achieved remarkable milestones. The official statement highly praised Caforio’s contributions, including his leadership of the landmark merger with Celgene, the launch of 12 new drugs, and the doubling of company revenues. These achievements have fostered a high-performance corporate culture and an engaged workforce.

However, these accomplishments present both inspiration and pressure for Boerner. BMS faces challenges in innovative drug development due to the expiration of patents on its three revenue pillars: Revlimid, Eliquis, and Opdivo. Together, these drugs generated $26 billion in sales in 2023, accounting for nearly 60% of the company's total revenue. The impending patent expirations create a sense of urgency for the company.

In response, BMS has been actively engaged in the M&A market, acquiring companies such as Karuna, Mirati, and RayzeBio for a combined total of approximately $22.9 billion. The company is also investing significantly in introducing innovative drugs, exemplified by the $8.3 billion licensing deal with Brii Biosciences for its dual-target ADC drug BL-B01D1.

For Boerner, these extensive acquisitions and introductions pose a formidable challenge, requiring time for integration and digestion.

At the financial report meeting on February 2, 2024, Boerner made his debut, presenting his comprehensive insights on the company’s future. Despite challenges like the patent cliff and the Inflation Reduction Act (IRA), Boerner emphasized that core products such as Revlimid, Eliquis, and Opdivo will continue to generate cash flow, supporting the company’s innovative R&D pipeline.

Boerner identified 2026 as the company's most challenging period, describing it as the “most critical risk exposure” due to the IRA’s impact taking effect in that year.

Boerner’s strategic focus in the current phase is to "shorten the transition period as much as possible" by accelerating R&D while maintaining strict cost control. His core strategy involves prioritizing investments in high-potential projects and suspending lower-priority ones.

For example, the acquisition of Karuna is not just about acquiring assets but also involves integrating its operating expenses. BMS needs to centralize management, improve efficiency, and free up resources for new assets.

From the outset of his tenure, Boerner has emphasized the importance of repositioning underperforming products such as Abecma and Zeposia, ensuring they receive adequate resources to succeed.

In July 2024, Eisai announced that its FRα ADC drug MORAb-202, which was part of a $3.1 billion collaboration, was returned by BMS. Despite high investment and strong performance in key areas, treatment-related adverse events such as interstitial lung disease/pneumonia limited its competitiveness.

In August 2024, BMS terminated its partnership with Agenus for TIGIT/CD96 dual antibodies, leading to a $200 million loss. Similarly, collaborations such as the $3 billion investment with Immatics have also been terminated. These actions reflect Boerner's strategy of shortening transition periods and focusing on the future.

So, who will be the next to face "return" at BMS?